LAVAL, QC, Oct. 30 /PRNewswire-FirstCall/ - Labopharm Inc. today announced that James R. Howard-Tripp, Chief Executive Officer of the Company, will present at the CIBC World Markets 18th Annual Healthcare Conference in New York City on Monday, November 5, 2007 at 3:40 p.m. ET.
Interested parties may access the live webcast for this presentation by visiting the “Events” section of the homepage of the Company’s website at www.labopharm.com. Please connect at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to join the webcast. An audio archive of the presentation will be available for 30 days.
About the CIBC World Markets 18th Annual Healthcare Conference
The CIBC World Markets 18th Annual Healthcare Conference will feature a core group of public and private companies who are pioneering the pharmaceutical, biotechnology, medical device, healthcare facility, healthcare technology and distribution, provider and service industries. Presentations will address topical issues such as Medicare and Medicaid reform, generic drug regulation, development of new blockbuster pharmaceutical and biotechnology products, product safety and patent issues, cross-border reimportation, Food and Drug Administration policy, managed care, and a comprehensive look at the current M&A environment.
About Labopharm Inc.
Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company’s lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm’s vision is to become a fully integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit www.labopharm.com.
This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process and the commercialization of the Company’s products thereafter, if they are approved. Investors should consult the Company’s ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.
CONTACT: At Labopharm, Mark A. D’Souza, Chief Financial Officer, Tel:
(450) 686-0207; At The Equicom Group, Jason Hogan, Media and Investor
Relations, Tel: (416) 815-0700, jhogan@equicomgroup.com; French: Eric
Bouchard, Tel: (514) 844-7997, ebouchard@equicomgroup.com
